BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 7796592)

  • 1. The effect of small doses of progesterone released from two types of vaginal rings on ovarian activity and bleeding patterns during the first postpartum year.
    Landgren BM; Jonsson B; Cekan SZ
    Contraception; 1995 Apr; 51(4):255-60. PubMed ID: 7796592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The comparative trial of TCu 380A IUD and progesterone-releasing vaginal ring used by lactating women.
    Chen JH; Wu SC; Shao WQ; Zou MH; Hu J; Cong L; Miao L; Wang C; Dong J; Gao J; Xiao BL
    Contraception; 1998 Jun; 57(6):371-9. PubMed ID: 9693396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contraceptives for lactating women: a comparative trial of a progesterone-releasing vaginal ring and the copper T 380A IUD.
    Sivin I; Díaz S; Croxatto HB; Miranda P; Shaaban M; Sayed EH; Xiao B; Wu SC; Du M; Alvarez F; Brache V; Basnayake S; McCarthy T; Lacarra M; Mishell DR; Koetsawang S; Stern J; Jackanicz T
    Contraception; 1997 Apr; 55(4):225-32. PubMed ID: 9179454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Luteinizing hormone releasing hormone agonist for contraception in breast feeding women.
    Fraser HM; Dewart PJ; Smith SK; Cowen GM; Sandow J; McNeilly AS
    J Clin Endocrinol Metab; 1989 Nov; 69(5):996-1002. PubMed ID: 2507572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contraception with progestogens and progesterone during lactation.
    Shaaban MM
    J Steroid Biochem Mol Biol; 1991; 40(4-6):705-10. PubMed ID: 1835650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pulsatile GnRH stimulates normal cyclic ovarian function in amenorrheic lactating postpartum women.
    Zinaman MJ; Cartledge T; Tomai T; Tippett P; Merriam GR
    J Clin Endocrinol Metab; 1995 Jul; 80(7):2088-93. PubMed ID: 7608260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progesterone-releasing vaginal rings for use in postpartum contraception. II. Pharmacokinetic profiles in women.
    Landgren BM; Hall PE; Cekan SZ
    Contraception; 1992 Apr; 45(4):343-9. PubMed ID: 1516366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The concentrations of urinary oestrone-3-glucuronide, LH and pregnanediol-3alpha-glucuronide as indices of ovarian function.
    Collins WP; Collins PO; Kilpatrick MJ; Manning PA; Pike JM; Tyler JP
    Acta Endocrinol (Copenh); 1979 Feb; 90(2):336-48. PubMed ID: 419920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of ovulation by low-dose mifepristone (RU 486).
    Ledger WL; Sweeting VM; Hillier H; Baird DT
    Hum Reprod; 1992 Aug; 7(7):945-50. PubMed ID: 1331167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct radioimmunoassay of urinary estrogen and pregnanediol glucuronides during the menstrual cycle.
    Stanczyk FZ; Miyakawa I; Goebelsmann U
    Am J Obstet Gynecol; 1980 Jun; 137(4):443-50. PubMed ID: 7386528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics and determinants of postpartum ovarian function in women in the United States.
    Campbell OM; Gray RH
    Am J Obstet Gynecol; 1993 Jul; 169(1):55-60. PubMed ID: 8333476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of RU486 administered during the proliferative and secretory phase of the cycle on the bleeding pattern, hormonal parameters and the endometrium.
    Swahn ML; Johannisson E; Daniore V; de la Torre B; Bygdeman M
    Hum Reprod; 1988 Oct; 3(7):915-21. PubMed ID: 2846630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breast-feeding and return to fertility: clinical evidence from Pakistan, Philippines and Thailand.
    Kennedy KI
    Asia Pac Popul J; 1990 Mar; 5(1):45-56. PubMed ID: 12283348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative study on the return to ovulation following chronic use of once-a-month injectable contraceptives.
    Bassol S; Hernandez C; Nava MP; Trujillo AM; Luz de la Cruz D
    Contraception; 1995 May; 51(5):307-11. PubMed ID: 7628206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immediate postpartum insertion of the norplant contraceptive device.
    Molland JR; Morehead DB; Baldwin DM; Castracane VD; Lasley B; Bergquist CA
    Fertil Steril; 1996 Jul; 66(1):43-8. PubMed ID: 8752609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of four different contraceptive vaginal rings: steroid serum levels, luteal activity, bleeding control and lipid profiles.
    Alvarez-Sanchez F; Brache V; Jackanicz T; Faundes A
    Contraception; 1992 Oct; 46(4):387-98. PubMed ID: 1486777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contraceptive effects of extended lactational amenorrhoea: beyond the Bellagio Consensus.
    Short RV; Lewis PR; Renfree MB; Shaw G
    Lancet; 1991 Mar; 337(8743):715-7. PubMed ID: 1672186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New IPPF statement on breastfeeding, fertility and post-partum contraception.
    International Planned Parenthood Federation IPPF. International Medical Advisory Panel IMAP
    IPPF Med Bull; 1990 Apr; 24(2):2-4. PubMed ID: 12316285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression of ovarian function with the transdermally given synthetic progestin ST 1435.
    Laurikka-Routti M; Haukkamaa M; Lähteenmäki P
    Fertil Steril; 1992 Oct; 58(4):680-4. PubMed ID: 1426309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pituitary, ovarian and endometrial effects of progesterone released prematurely during the proliferative phase.
    Shumin X; Johannisson E; Landgren BM; Diczfalusy E
    Contraception; 1983 Feb; 27(2):177-93. PubMed ID: 6851555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.